Aug 7 (Reuters) - Britain's National Health Service(NHS)
will begin rolling out Vertex Pharmaceuticals ( VRTX ) and
CRISPR Therapeutics' gene therapy to treat rare blood
disorder beta thalassemia, Vertex said in a statement on
Wednesday.